Seroatlas · Human Serome Atlas

ABT1

Activator of basal transcription 1

Also known as: ABT1_HUMAN, Esf2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9ULW3
Gene: ABT1
Ensembl: ENSG00000146109
Chromosome: 6
Canonical length: 272 aa
Protein class: Predicted intracellular proteins
Subcellular location: Vesicles

OverviewNCBI Gene

Basal transcription of genes by RNA polymerase II requires the interaction of TATA-binding protein (TBP) with the core region of class II promoters. Studies in mouse suggest that the protein encoded by this gene likely activates basal transcription from class II promoters by interaction with TBP and the class II promoter DNA. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

272 residues, UniProt reviewed canonical sequence.

>Q9ULW3|ABT1
     1  MEAEESEKAA TEQEPLEGTE QTLDAEEEQE ESEEAACGSK KRVVPGIVYL GHIPPRFRPL
    61  HVRNLLSAYG EVGRVFFQAE DRFVRRKKKA AAAAGGKKRS YTKDYTEGWV EFRDKRIAKR
   121  VAASLHNTPM GARRRSPFRY DLWNLKYLHR FTWSHLSEHL AFERQVRRQR LRAEVAQAKR
   181  ETDFYLQSVE RGQRFLAADG DPARPDGSWT FAQRPTEQEL RARKAARPGG RERARLATAQ
   241  DKARSNKGLL ARIFGAPPPS ESMEGPSLVR DS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ABT1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.48
Highest tissue expression: 22 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 22 nTPM
lymph node: 15 nTPM
spleen: 14 nTPM
skin: 14 nTPM
esophagus: 13 nTPM
liver: 13 nTPM

Single-cell type

late spermatids: 142 nCPM
extravillous trophoblasts: 117 nCPM
migrating cytotrophoblasts: 117 nCPM
syncytiotrophoblasts: 116 nCPM
cytotrophoblasts: 110 nCPM
esophageal suprabasal cells: 79 nCPM

Immune cell

total PBMC: 88 nTPM
T-reg: 77 nTPM
basophil: 76 nTPM
naive B-cell: 71 nTPM
naive CD4 T-cell: 68 nTPM
memory B-cell: 67 nTPM

Brain region

cerebellum: 8.8 nTPM
cerebral cortex: 6.7 nTPM
white matter: 6.6 nTPM
basal ganglia: 6.4 nTPM
thalamus: 6.4 nTPM
amygdala: 6.2 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.01
gnomAD pLI: 0.02
gnomAD missense Z: 0.17
DepMap mean gene effect: -1.16
DepMap dependency class: common

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 9% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

Nucleotide-binding alpha-beta plait domain superfamily
RNA-binding domain superfamily
ABT1/ESF2, RNA recognition motif
ABT1/Esf2

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of ABT1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ABT1 as an antibody target. Whether an autoantibody or antibody against ABT1 could matter depends on whether native ABT1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ABT1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ABT1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...